Image guided percutaneous thermal ablation is widely used for patients with primary or secondary liver tumors who do not qualify for surgical resection. The COVER-ALL study is a randomized Phase II clinical trial that evaluates the impact of using software aid in confirming probe position and ablation coverage. Current practice in the trial involves acquisition of a pre-procedure contrast enhanced computed tomography (CECT) scan for gross tumor volume (GTV) definition and non-contrast CT after probe placement, followed by a biomechanical model-based deformable image registration (Morfeus) between the two scans to map the GTV onto the non-contrast CT for position confirmation. CT scan length that covers the entire liver is needed for Morfeus. In this work, we investigated an alternative workflow with a reduced length non-contrast CT using image padding on the first 50 COVER-ALL trial patients. The full-length non-contrast CT was first cropped to a fixed thickness, ranging from 2.5-7.5 cm, along the GTV. The remaining volume was padded with the CECT based on intensity-based deformable image registration (DIR). Morfeus DIR was performed between the CECT and resultant padded non-contrast CT to map the GTV segmentation from CECT to padded non-contrast CT. The GTV mapping results were compared to the original GTV mapping results performed on the full-length CT. The median mapping differences using cropping thickness of 7.5 cm was 1.2 (0.5-2.3) mm, with only 3 cases having larger than 5 mm discrepancies. The comparable DIR performance suggests the feasibility of acquiring a reduced-length non-contrast CT to maintain image registration accuracy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.